Will ARGX break out ascending channel

2021年2月4日

Will Argenx be Wall streets next Biotech unicorn? I am extremely bullish!

Biotech is booming business. Monoclonal antibodies are revolutionizing pharma industry.

Again great news for Argenx.

01feb2021
launches new global offering to raise funds after 'Go' decisions for CIDP treatment trials
https://www.argenx.com/news/argenx-announces-go-decision-adhere-trial-efgartigimod-chronic-inflammatory-demyelinating
https://www.argenx.com/news/argenx-announces-launch-proposed-global-offering-1


02feb2021
Argenx raises $1 bln
https://www.argenx.com/news/argenx-raises-10-billion-gross-proceeds-global-offering

statement showing their product is might be much better than competitors
https://www.argenx.com/news/argenx-issues-statement-concerning-efgartigimod


Products are yet to be approved by FDA.
Current products that are currently in clinical trials are:

• Efgartigumod
  
  Phase 3 trials submitted for Mystenias gravis/MG (1.4 million patients worldwide)
  Phase 3 trials ongoing for Immune Thrombocytopenia/ITP (200 thousand patients worldwide)
  Phase 2 trials ongoing for Chronic inflammatory Demyelinating polyneuropathy/CIDP (300 thousand patients worldwide)
  Phase 2 trials ongoing for Pemphigus Vulgaris/PV (200 thousand patients worldwide)
  This products aims to treat over 2 million patients worldwide. IF this products proves to have a high enough efficacy Argenx wil immediately have hit the jackpot.
  
  
• Cusatuzumab (in cooperation with J&J)
  
  Phase 2 trials ongoing for Accute Myeloid Leukemia (AML) (incidence 4.3 to 100.000 and a death rate 2.8 to 100.000 which is extremely high)
  At some point in our life we all have been confronted with cancer. Sayings like 'it always has to happen to the best of us' don't exist for nu reason. Curing cancer isn't only a billion dollar quest(ion). It's a matter of life and death.
  Phase 2 trials ongoing for Higher-risk Myelodysplastic Syndromes (MDS) (approximate prevalence op 150 thousand people affected worldwide)
  Cusatuzumab again might work out to become a flagship product product for Argenx.
  

Argenx pipeline products show immense promise. The company's market cap is still on the low side compared to other pharma companies with working products. Possible upside to be a multiple of the current market cap.
Current market cap. 16.695bln as of 03feb2021


Compared to other biotech companies as of 03feb2021
Alexion Pharmaceuticals $33.84 bln
Regeneron: $52.41 bln
Vertex Pharmaceuticals $54.84 bln
Novo Nordisk $167.60 bln


If Argenx keeps doing great, FDA approves efgartigumod and stock price remains in this ascending channel Stock will double within 2 years time.
ARGX might even break out above this channel coming days